Studies have shown that the more effective tumor‐specific antigens are formed, the better the efficacy of PD‐1/PD‐L1 blockers is, and it is related to the clinical PFS (progression‐free survival) of patients, such as highly immunogenic melanoma, renal cell carcinoma, and non‐small cell lung cancer. Here, PDCD1 is linked to melanoma.